Technical Analysis for GNTA - Genenta Science S.p.A.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | 14.28% | |
| MACD Bearish Signal Line Cross | Bearish | 14.28% | |
| New 52 Week Closing Low | Bearish | 14.28% | |
| Stochastic Sell Signal | Bearish | 14.28% | |
| Expansion Breakdown | Bearish Swing Setup | 14.28% |
| Alert | Time |
|---|---|
| Possible NR7 | about 17 hours ago |
| Possible Inside Day | about 17 hours ago |
| 60 Minute Opening Range Breakout | about 20 hours ago |
| Up 10% | about 20 hours ago |
| Gap Up Partially Closed | about 20 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Cell Biology Gene Therapy Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Cell Biology Gene Therapy Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.8099 |
| 52 Week Low | 2.2 |
| Average Volume | 5,816 |
| 200-Day Moving Average | 4.85 |
| 50-Day Moving Average | 3.82 |
| 20-Day Moving Average | 3.40 |
| 10-Day Moving Average | 3.42 |
| Average True Range | 0.39 |
| RSI (14) | 39.76 |
| ADX | 23.44 |
| +DI | 13.53 |
| -DI | 38.58 |
| Chandelier Exit (Long, 3 ATRs) | 2.80 |
| Chandelier Exit (Short, 3 ATRs) | 3.36 |
| Upper Bollinger Bands | 4.05 |
| Lower Bollinger Band | 2.75 |
| Percent B (%b) | 0.12 |
| BandWidth | 38.13 |
| MACD Line | -0.16 |
| MACD Signal Line | -0.12 |
| MACD Histogram | -0.0341 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.39 | ||||
| Resistance 3 (R3) | 3.36 | 3.17 | 3.31 | ||
| Resistance 2 (R2) | 3.17 | 3.05 | 3.19 | 3.28 | |
| Resistance 1 (R1) | 3.04 | 2.98 | 3.11 | 3.07 | 3.25 |
| Pivot Point | 2.86 | 2.86 | 2.89 | 2.87 | 2.86 |
| Support 1 (S1) | 2.73 | 2.74 | 2.79 | 2.76 | 2.57 |
| Support 2 (S2) | 2.54 | 2.66 | 2.56 | 2.55 | |
| Support 3 (S3) | 2.41 | 2.54 | 2.52 | ||
| Support 4 (S4) | 2.44 |
